<DOC>
	<DOCNO>NCT00792246</DOCNO>
	<brief_summary>Determine much voriconazole absorb product give mouth child extensive graft versus host disease stem cell transplantation determine correct dose voriconazole population . Hypothesis : Children gastrointestinal graft versus host disease decrease absorption oral voriconazole require high dos voriconazole order prevent treat fungal infection .</brief_summary>
	<brief_title>Voriconazole Pharmacokinetics Children With Gastrointestinal Graft Versus Host Disease</brief_title>
	<detailed_description>Disseminated fungal infection lead cause mortality child receive hematopoietic stem cell transplantation ( SCT ) . Therefore , child routinely receive prophylactic empirical antifungal therapy SCT . The commonly used antifungal agent population voriconazole . Voriconazole give via intravenous oral route child post SCT routinely switch intravenous oral formulation time hospital discharge . However , absorption systemic exposure oral voriconazole well-described child . Furthermore , many child undergo transplantation develop gastrointestinal graft versus host disease likely impact oral absorption . The magnitude effect result graft versus host disease absorption voriconazole subsequent blood concentration child unknown . Thus child graft versus host disease particularly high risk inadequate absorption subsequent sub-therapeutic level voriconazole . They may need high frequent dose achieve therapeutic level . The purpose research project define pharmacokinetics oral voriconazole establish dose guideline child follow SCT .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Age â‰¤ 18 year , sufficient venous access permit administration voriconazole , ability take oral medication , write informed consent provide parent legally authorize representative , Grade II high ( extensive ) gastrointestinal graft versus host disease patient graft versus host disease patient subset . History anaphylaxis attribute voriconazole triazole compound , concomitant condition , opinion investigator would preclude patient 's participation study , previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pediatric</keyword>
	<keyword>bioavailability</keyword>
</DOC>